The Covid-19, Epidemiology, Clinic and Prevention

Author(s): Alessandro Antonelli*, Giusy Elia, Silvia Martina Ferrari, Rudy Foddis, Salvatore De Marco, Alfonso Cristaudo, Poupak Fallahi

Journal Name: Current Genomics

Volume 21 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Xie, M.; Chen, Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int. J. Infect. Dis., 2020, 94, 119-124.
[2]
World Health Organization. WHO Director-General’s opening remarks at the mission briefing on COVID -19-26 February, 2020. Available from:https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---26-february-2020 (Accessed April 2020).
[3]
Onder, G.; Rezza, G.; Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA, 2020. [Epub ahead of print]
[4]
Velavan, T.P.; Meyer, C.G. The COVID-19 epidemic. Trop. Med. Int. Health, 2020, 25(3), 278-280.
[5]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[6]
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (16-24 February 2020). Available from:https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (Accessed April 2020).
[7]
Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.X.; Wang, Y.Y.; Xiao, G.F.; Shi, Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798), 270-273.
[8]
Iacobellis, G. COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res. Clin. Pract., 2020, 162, 108125
[9]
World Health Organization: Q&A on coronaviruses (COVID-19), 2020. Available from:https://www.who.int/news-room/q-a-detail/q-a-coronaviruses (Accessed April 2020).
[10]
European Centre for Disease Prevention and Control. Q&A on COVID-19., Available from:https://www.ecdc.europa.eu/en/covid-19/questions-answers (Accessed April 2020).
[11]
Centers for Disease Control and Prevention Coronavirus Disease 2019 (COVID-19). Environmental Cleaning and Disinfection Recommendations., Available from:https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/cleaning-disinfection.html (Accessed April 2020).
[12]
World Health Organization Coronavirus disease 2019 (COVID-19) Situation Report 73.. Available from:https://www.google.com/ search?channel=crow2&client= firefox-b-d&q=Coronavirus+disease+2019+(COVID-19)+Situation+Report+–+73(Accessed April 2020).
[13]
Lake, M.A. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med. (Lond.), 2020, 20(2), 124-127.
[14]
Li, Y.; Xia, L. Coronavirus Disease 2019 (COVID-19): role of chest CT in diagnosis and management. AJR Am. J. Roentgenol., 2020, 4, 1-7.
[15]
Ai, T.; Yang, Z.; Hou, H.; Zhan, C.; Chen, C.; Lv, W.; Tao, Q.; Sun, Z.; Xia, L. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology, 2020, 200642
[16]
Radiological Society of North America. Science Daily: CT provides best diagnosis for COVID-19. Available from:www.sciencedaily.com/releases/ 2020/02/200226151951.htm (Accessed April, 2020).
[17]
] World Health Organization: Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance (Accessed April, 2020).
[18]
Centers for Disease Control and Prevention: Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus. Available from:https://www.cdc.gov/ coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf (Accessed April, 2020).
[19]
Ferrari, S.M.; Fallahi, P.; Mancusi, C.; Colaci, M.; Manfredi, A.; Ferri, C.; Antonelli, A. HCV-related autoimmune disorders in HCV chronic infection. Clin. Ter., 2013, 164(4), e305-e312.
[20]
Thachil, J. The versatile heparin in COVID-19. J. Thromb. Haemost., 2020, 18(5), 1020-1022.
[21]
Zhou, Y.; Zhang, Z.; Tian, J.; Xiong, S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann. Palliat. Med., 2020, 9(2), 428-436.
[22]
Xiong, Y.; Liu, Y.; Cao, L.; Wang, D.; Guo, M.; Jiang, A.; Guo, D.; Hu, W.; Yang, J.; Tang, Z.; Wu, H.; Lin, Y.; Zhang, M.; Zhang, Q.; Shi, M.; Liu, Y.; Zhou, Y.; Lan, K.; Chen, Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect., 2020, 9(1), 761-770.
[23]
Zhang, C.; Wu, Z.; Li, J.W.; Zhao, H.; Wang, G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents, 2020. 105954 [Epub ahead of print]
[25]
Giwa, A.L.; Desai, A.; Duca, A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emerg. Med. Pract., 2020, 22(5), 1-28.
[26]
Li, G.; De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov., 2020, 19(3), 149-150.
[27]
Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799.
[28]
Md Insiat Islam Rabby. Current drugs with potential for treatment of COVID-19: a literature review. J. Pharm. Pharm. Sci., 2020, 23(1), 58-64.
[29]
Tignanelli,, C.J.; Ingraham,, N.E.; Sparks,, M.A.; Reilkoff, R.; Bezdicek, T.; Benson, B.; Schacker, T.; Chipman, J.G.; Puskarich, M.A. Antihypertensive drugs and risk of COVID-19? Lancet Respir. Med., 2020, 8(5) e29
[30]
Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost., 2020, 18(5), 1094-1099.
[31]
Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T.; Honoré, S.; Colson, P.; Chabrière, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 2020. 105949 [Epub ahead of print]
[32]
Molina, J.M.; Delaugerre, C.; Goff, J.L.; Mela-Lima, B.; Ponscarme, D.; Goldwirt, L.; de Castro, N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med. Mal. Infect., 2020, 50(4), 384.
[33]
Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178 [Epub ahead of print]
[34]
Casadevall, A.; Pirofski, L.A. The convalescent sera option for containing COVID-19. J. Clin. Invest., 2020, 130(4), 1545-1548.
[35]
World Health Organization: Coronavirus disease (COVID-19) advice for the public. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public (Accessed April 2020).
[36]
Centers for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-19). Travel-Associated Exposures., Available from:https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html (Accessed April 2020).
[37]
Steps to help prevent the spread of COVID-19 if you are sick. Available from:https://www.cdc.gov/coronavirus/2019-ncov/downloads/sick-with-2019-nCoV-fact-sheet.pdf (Accessed April 2020).
[38]
Centers for Disease Control and Prevention: What healthcare personnel should know about caring for patients with confirmed or possible coronavirus disease 2019 (COVID-19). Available from:https://www.cdc.gov/coronavirus/2019-ncov/hcp/caring-for-patients-H.pdf(Accessed April 2020).
[39]
Cascella, M.; Rajnik, M.; Cuomo, A.; Dulebohn, S.C.; Di Napoli, R. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing;, 2020.
[40]
Chen, W.H.; Strych, U.; Hotez, P.J.; Bottazzi, M.E. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep., 2020, 1-4.
[41]
Roberts, M. BBC News: Coronavirus US volunteers test first vaccine., Available from:https://www.bbc.com/news/health-51906604 (Accessed April 2020).
[42]
Agrawal, S.; Goel, A.D.; Gupta, N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch. Chest Dis., 2020, 90(1)


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 3
Year: 2020
Published on: 09 July, 2020
Page: [157 - 160]
Pages: 4
DOI: 10.2174/1389202921999200427133052

Article Metrics

PDF: 22
HTML: 1